Immunovia’s Pancreatic Cancer Blood Test is World’s First for Early Disease Detection

Pancreatic cancer generally has a poor prognosis because it is often diagnosed in later stages; however, a new blood test developed by Swedish diagnostic firm Immunovia may soon change that.

Immunovia’s diagnostic is called the IMMray PanCan-d test, a blood test for the early detection of pancreatic cancer, and it has been approved by the Massachusetts Department of Public Health, which has already begun using it to test patients for the deadly cancer. The approval was granted to the American subsidiary of the company, Immunovia, Inc., which is located in Massachusetts, on August 3.